The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "May 2016.”
According to the above filters, the following are recent buys and sells from company insiders in the past week.
On May 12, Mangrove Partners Fund, 10% owner of Asta Funding Inc. (ASFI), bought 1,903,274 shares in the company at the price of $10.34 per share. Since then, the price of the stock has dropped by 1.0% to $10.24.
The company has an insider ownership of 10.59%, an institutional ownership of 73.91% and together with its wholly owned operating subsidiaries is engaged in the business of acquiring, managing, servicing and recovering portfolios of consumer receivables.
During the last 12 months, the price of the stock has risen by 23% and is now trading with a P/B ratio of 0.69. The price is 1.92% below its 52-week high and 50.15% above its 52-week low.
On May 10, Phillip Frost M.D. et al, 10% owner of Tiger X Medical Inc. (CDOM), bought 114,937,148 shares, and Thomas H. Morgan and Ronald N. Richards, directors of Tiger X Medical Inc., and Andrew A. Brooks, CEO and 10% owner, and Jonathan Brooks, director and 10% owner, sold a combined 103,917,532 shares in the company at the price of 10 cents per share. Since then, the price of the stock has risen by 30% to 13 cents.
The company has an institutional ownership of 0.22% and insider ownership of 52.43%. It is a development stage company. It was previously engaged in designing, developing and marketing reconstructive joint devices and spinal surgical devices in the U.S.
The stock is now trading with a P/B ratio of 1.48. The price is 4.96% below its 52-week high and 162.75% above its 52-week low.
On May 9, Phillip Frost M.D. et al, director and 10% owner of IDI Inc. (IDI), bought 2.19 million shares in the company at the price of $4.80 per share. Since then, the price of the stock has risen by 18.3% to $5.68.
The company has an insider ownership 26.61% and institutional ownership of 4.30%. Through its subsidiaries it is engaged in data analytics, serving as an information solutions provider to the risk management industry for due diligence, risk assessment, fraud detection and prevention and authentication and verification.
During the last 12 months, the price of the stock has dropped by 15% and is now trading with a P/B ratio of 1.18.
On May 9, Barry C. Hoing, director and 10% owner of Pershing Gold Corp. (PGLC), bought 815,041 shares in the company at the price of $3.65 per share. Since then, the price of the stock has risen by 6% to $3.87.
The company has an insider ownership of 99.06% and an institutional ownership of 15.16%. It is in the exploration stage. It is a gold and precious metals exploration company pursuing exploration and development opportunities mainly in Nevada.
During the last 12 months, the price of the stock has risen by 35% and is now trading with a P/B ratio of 2.54. The price is 38.57% below its 52-week high and 27.30% above its 52-week low.
Most important sales of the week
On May 11, Lal Family Partners L.P., 10% owner of The Estee Lauder Companies Inc. (EL), sold 500,000 shares in the company at the price of $94.41 per share. Since then, the price of the stock has risen by 0.2% to $94.61.
The company has an insider ownership of 0.21% and institutional ownership of 59.51%. The company is engaged in manufacturing and marketing skin care, makeup, fragrance and hair care products.
During the last 12 months, the price of the stock has risen by 8% and is now trading with a P/B ratio of 9.37. The price is 2.94% below its 52-week high and 28.42% above its 52-week low.
On May 9, Pershing Square Capital Management, director of Zoetis Inc. (ZTS), sold 16.85 million shares in the company at the price of $46.55 per share. Since then, the price of the stock has dropped by 0.6% to $46.25.
The company has an institutional ownership of 88.22% and insider ownership of 0.04%. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.
During the last 12 months, the price of the stock has risen by 1% and is now trading with a P/B ratio of 19.65. The price is 16.49% below its 52-week high and 22.58% above its 52-week low.
On May 10, Henry R. Kravis, KKR Millennium Fund L.P. and KKR PEI Investments L.P., 10% owners of HCA Holdings Inc. (HCA), collectively sold 28,082,874 shares in the company at the price of $80.12 per share. Since then, the price of the stock has dropped by 3% to $77.69.
The company has an institutional ownership of 90.98% and insider ownership of 0.26%. It is a health care services company in the U.S. It operates 166 hospitals, comprised of 162 general, acute care hospitals, three psychiatric hospitals and one rehabilitation hospital. In addition, it operates 113 freestanding surgery centers.
During the last 12 months, the price of the stock has not changed and is now trading with a P/E ratio of 14.62. The price is 2.47% below its 52-week high and 76.93% above its 52-week low.
Start a free seven-day trial of Premium Membership to GuruFocus.
